Tests dendritic cell vaccines in multiple myeloma patients in remission
Tests whether engineered dendritic cell vaccines are feasible and safe in multiple myeloma.
Key facts
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Where
- Shenzhen, ChinaSee the site
- Trial code
- Registry title
- Engineered Dendritic Cell Vaccines for Multiple Myeloma
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Starts
- 30 Jun 2027
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- DC vaccines
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma or plasmacytoma who are in very good partial or complete remission after earlier combination treatment. It tests a dendritic cell vaccine to help keep the remission going.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Multiple myeloma or plasmacytoma in very good partial remission or complete remission.
- Earlier treatment
- Earlier combination therapies, after which the disease is in very good partial or complete remission. Use of systemic steroids at the same time is not allowed.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Uncontrolled active infection
- HIV or active hepatitis B or hepatitis C infection
- Taking systemic steroids at the same time (inhaled steroids are fine)
- Expected survival of 12 weeks or less
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male and female subjects with multiple myeloma or plasmacytoma
- Very good partial or complete remission (CR) after prior combination therapies
- Expected survival > 12 weeks
- Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
- Voluntary informed consent is given with willingness to continue follow up
Who cannot take part
- Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
- Uncontrolled active infection
- HIV or active hepatitis B or hepatitis C infection
- Pregnant or lactating women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, ph.DNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
The group in the trial
- DCvac cells to treat MMTreatment being tested
Treatment: DC vaccines
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
- Plain-language title
- Tests dendritic cell vaccines in multiple myeloma patients in remissionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06435910, who can take part
- Record updated
- 2 November 2026